BoironLTS:0DTF 73 Operating Margin % is 8.08% as of Dec. 2025, which is 32% below its 10-year median of 11.90. GuruFocus rates LTS:0DTF with a GF Score™ of 73/100 and a GF Value™ of €33.63 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Boiron ranks worse than 50.58% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Boiron's Operating Income for the
six
months ended in Dec. 2025 was €20.7 Mil. Boiron's Revenue for the
six
months ended in Dec. 2025 was €255.5 Mil. Therefore, Boiron's Operating Margin % for the quarter that ended in Dec. 2025 was 8.08%.
Warning Sign:
Boiron SA operating margin has been in a 5-year decline. The average rate of decline per year is -10.5%.
The historical rank and industry rank for Boiron's Operating Margin % or its related term are showing as below:
LTS:0DTF'
s Operating Margin % Range Over the Past 10 Years
Min: 7.26 Med: 11.9 Max: 21.07
Current: 7.26
LTS:0DTF's Operating Margin % is ranked worse than 50.58% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs LTS:0DTF: 7.26
Boiron's 5-Year Average Operating Margin % Growth Rate was -10.50% per year.
Boiron's Operating Income for the
six
months ended in Dec. 2025 was €20.7 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was €36.4 Mil.
Boiron (LTS:0DTF) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Boiron Operating Margin % Related Terms
Boiron Operating Margin % Historical Data
* Premium members only.
The historical data trend for Boiron's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DTF vs ZTS, UTHR, VTRS: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boiron Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Boiron's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Boiron's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Boiron's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boiron (LTS:0DTF) has a Operating Margin % of 8.08% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Boiron and its competitors. This is 32% below median its historical median of 11.90. Over the past decade, Boiron's Operating Margin % has ranged from 7.26 to 21.07. According to the industry distribution chart, Boiron ranks #483 out of 955 companies in the Drug Manufacturers industry, placing it in the top 50.6%.
Is Boiron's Operating Margin % too high?
Boiron's current Operating Margin % of 8.08% is 32% below median its 10-year median of 11.90. Over the past 10 years, this metric has ranged from a low of 7.26 to a high of 21.07. The Drug Manufacturers industry median Operating Margin % is 7.45. Boiron's value of 8.08% is 8.5% above this industry median. Based on the distribution chart, Boiron ranks #483 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Boiron has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boiron's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Boiron ranks #483 out of 955 companies for Operating Margin %. This places Boiron in the lower half of its industry. The industry median Operating Margin % is 7.45. Boiron's value of 8.08% is 8.5% above this benchmark. Historically, Boiron's own Operating Margin % has ranged from 7.26 to 21.07 over the past decade. While the company's 10-year median is 11.90 vs. the industry median of 7.45, Boiron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boiron's current Operating Margin % of 8.08% is 8.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Boiron and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boiron's current Operating Margin % is 8.08%, which is 32% below median its own 10-year median of 11.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boiron stock overvalued right now?
Based on GuruFocus' analysis, Boiron (LTS:0DTF) is currently considered Modestly Undervalued. The stock's GF Value™ is €33.63, compared to a current price of €27.70 — trading 17.6% below its estimated fair value. The current Operating Margin % is 8.08%, which is 32% below median its 10-year median of 11.90 and 8.5% above the Drug Manufacturers industry median of 7.45. Boiron's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Boiron (LTS:0DTF), the current Operating Margin % is 8.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boiron (LTS:0DTF) Overvalued in 2026?
Based on GuruFocus' analysis, Boiron stock appears to be undervalued.
The current stock price of €27.70 is trading 17.6% below its estimated GF Value™ of €33.63.
GuruFocus considers Boiron to be Modestly Undervalued.
Key valuation signals for LTS:0DTF:
Operating Margin %: 8.08% (32% below median its 10-year median of 11.90)
GF Value™: €33.63 vs. price of €27.70 (17.6% below fair value)
Industry Position: 8.5% above the Drug Manufacturers median (#483 of 955)
No single metric tells the full story. See the LTS:0DTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
73GF Score
Get the complete analysis for LTS:0DTF
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DTF has been successfully added to your 
